Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 103,144,832
  • Shares Outstanding, K 1,636,700
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.18
  • Price/Sales 5.26
  • Price/Cash Flow 20.32
  • Price/Book 6.85

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.15 +5.64%
on 11/20/17
63.87 -0.52%
on 12/04/17
+2.68 (+4.40%)
since 11/10/17
3-Month
59.79 +6.27%
on 10/27/17
66.10 -3.87%
on 10/13/17
+0.52 (+0.83%)
since 09/12/17
52-Week
46.01 +38.10%
on 01/26/17
66.10 -3.87%
on 10/13/17
+6.99 (+12.36%)
since 12/12/16

Most Recent Stories

More News
PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an "armed" oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing...

BMY : 63.47 (+0.71%)
Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study

Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

AZN : 33.35 (+0.69%)
CLVS : 63.44 (+0.86%)
PFE : 36.65 (+1.22%)
BMY : 63.47 (+0.71%)
Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS(R) (Brentuximab Vedotin) and Opdivo(R) (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma

---Combination Data Showed 83 Percent Objective Response Rate and 62 Percent Complete Response Rate with an Acceptable Safety Profile in Pre-Transplant Relapsed or Refractory Classical Hodgkin Lymphoma...

SGEN : 53.99 (-2.30%)
BMY : 63.47 (+0.71%)
Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

--14.2% of patients treated with Sprycel induction therapy received stem cell transplant in first remission

BMY : 63.47 (+0.71%)
Bristol-Myers Squibb Announces Dividend Increase

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.6% percent in the company's quarterly dividend, beginning in the first quarter of ...

BMY : 63.47 (+0.71%)
Cell Medica Announces Appointment of Industry Leader Dr Annalisa Jenkins as Chair

Cell Medica (or 'the Company'), a leader in next generation cellular immunotherapies for the treatment of cancer, today announced the appointment of Annalisa Jenkins, MBBS, FRCP, as Chair...

MRK : 56.80 (+0.82%)
BMY : 63.47 (+0.71%)
Cocoon Biotech Appoints Dr. Annalisa Jenkins as Executive Chair of the Board

Cocoon Biotech, Inc., a biotechnology company with a broad drug delivery platform and an initial focus in ophthalmology and osteoarthritis, today announced that the company has appointed Annalisa Jenkins,...

DMTX : 5.95 (-0.42%)
BMY : 63.47 (+0.71%)
Bristol-Myers Squibb and Pfizer Alliance Urge People to 'Tune in to AFib, Take Note of Stroke Risk'

The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched 'Tune in to AFib, Take Note of Stroke Risk' to educate the estimated nearly seven...

PFE : 36.65 (+1.22%)
BMY : 63.47 (+0.71%)
Consolidated Research: 2018 Summary Expectations for Skechers U.S.A., Bristol-Myers Squibb, Mastercard, Container Store, Signature Bank, and Bridgepoint Education -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Skechers U.S.A., Inc. (NYSE:SKX),...

SKX : 36.45 (+0.03%)
MA : 152.49 (+1.07%)
TCS : 5.59 (-1.41%)
BPI : 8.99 (+1.81%)
SBNY : 136.15 (-0.18%)
BMY : 63.47 (+0.71%)
This Morning's Technical Outlook on Drug Makers Stocks -- Bristol-Myers Squibb, Eli Lilly, AbbVie, and Johnson & Johnson

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on BMY, LLY, ABBV, and JNJ which is a click away at www.wallstequities.com/registration....

JNJ : 143.02 (+1.33%)
LLY : 86.20 (-0.54%)
ABBV : 94.92 (-1.61%)
BMY : 63.47 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human...

See More

Key Turning Points

2nd Resistance Point 64.16
1st Resistance Point 63.59
Last Price 63.47
1st Support Level 62.27
2nd Support Level 61.52

See More

52-Week High 66.10
Last Price 63.47
Fibonacci 61.8% 58.43
Fibonacci 50% 56.06
Fibonacci 38.2% 53.68
52-Week Low 46.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.